Crowdonomics
Facible BioDiagnostics, Inc.

Reg A+ · Equity · May 2022

ClosedReg A+Equity
via the platform · last checked Aug 16, 2026
Raised
$0 / $36.7M max
0% of ceiling
Investors
—
—
Estimated pre-money
$388.4M
—

Financials disclosed in this offering

FY2021 · hover for source
$0
−$6.4M
FY2021
RevenueNet income
Metric
FY2021 audited
Income statement
Revenue
$0
Cost of goods sold
$2,205,884
Net income
-$6,377,124
Balance sheet
Cash
$449,114
Accounts receivable
$0
Total assets
$1,432,437
Long-term debt
$8,805,465
Total liabilities
$9,070,128
Other
Headcount
8

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Amendments to this offering

4 amendments
  1. Oct 7, 2022
    Terms not yet extracted from this filing
    Form 1-A POS on EDGAR ↗
  2. Sep 20, 2022
    Terms not yet extracted from this filing
    Form 1-A POS on EDGAR ↗
  3. Aug 9, 2022
    Terms not yet extracted from this filing
    Form 1-A POS on EDGAR ↗
  4. Jul 21, 2022
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. Form 1-A amendments state no reason; those filed before qualification are usually responses to SEC staff review.

Deal terms

Est. pre-money$388.4M
Price / share$5.80
Shares offered6,896,552

Estimated, not stated: $5.80 × 66,961,666 securities outstanding.

Offering details

Target—
Max$36,666,667
Min investment—
OpenedMay 9, 2022
Deadline—
Days active1,613

Links & provenance

Source: SEC EDGAR
0001910594-22-000005
Last synced Aug 16, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.